Lanfear Dennis M 4

4 · Coherus BioSciences, Inc. · Filed Nov 24, 2023

Form 4

Period: 2023-11-22

DirectorPresident & CEO

Transactions

Exercise/Conversion
Common Stock
2023-11-22$1.42/sh+258,940$366,918→ 954,793 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-22−299,940→ 0 total
Exercise: $1.42Exp: 2023-11-22→ Common Stock (299,940 underlying)
Exercise/Conversion
Common Stock
2023-11-22$1.42/sh+41,000$58,097→ 695,853 total
Sale
Common Stock
2023-11-22$2.02/sh−223,100$449,770→ 731,693 total

Holdings

Footnotes (6)

[F1]For part of the stock option, this represents a cash exercise-and-hold transaction where cash was paid by the Reporting Person for the exercise price and anticipated taxes.
[F2]For the remaining part of the stock option, this represents a cashless exercise-and-hold transaction where only enough shares were sold to cover the exercise price, anticipated taxes and broker's fee, and the remaining shares were held by the Reporting Person.
[F3]This transaction was executed in multiple trades at prices ranging from $2.000 to $2.055. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
[F5]These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
[F6]The underlying shares subject to the option vested and became exercisable in successive, equal monthly installments over four years measured from July 20, 2013.

Documents

1 file